Home >> About Us >> Company History
 

About Us

 Company History
   The Team
   Partners
Company History
 

2011
  • June: Announced positive results from Phase IIa trial in 200 adult participants.  Both primary and secondary endpoints met.  
  • February: Positive interim safety results announced

2010
  • November: Raised $1.25m using Yorkville SEDA
  • October: Commenced immunizations in first Phase II clinical trial
  • August: Received Ethics ('Helsinki') Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine
  • July: Received Frost & Sullivan '2010 European Influenza Vaccines Technology Innovation Award'
  • June: Received third annual consecutive grant from Israeli Office of Chief Scientist for $1 million towards the development of the Universal Influenza Vaccine
  • April: Announced final safety and immunogenicity results from second Phase I/II trial - Multimeric-001 successfully activates both humoral and cellular arms of the immune system, stimulating responses against both Type A and B Influenza strains
  • March: Announced positive interim safety results from the second Phase I/II trial in 60 elderly participants - the Multimeric-001 was found to be safe and well tolerated
  • February: Signed a term sheet with Yorkville Advisers for the provision of a standby equity facility of up to $7m over three years

2009
  • December: Raised $5.3m in a secondary offering on the Tel Aviv Stock Exchange
  • December: Announced immunogenicity results from first Phase I/II trial - Multimeric-001 successfully activates both humoral and cellular arms of the immune system, stimulating responses against both Type A and B Influenza strains
  • October: Initiated subsequent Phase I/II trial in 60 healthy elderly volunteers
  • August: Reported initial safety results from first Phase I/II trial - no significant adverse events found
  • June: Initiated Phase I/II trial in 63 healthy adult volunteers
  • February: Concluded GLP toxicology study

2008
  • November: Commenced a repeated (3 dose) GLP toxicology study using the maximal human dose
  • July: Pre-IND Meeting.  BiondVax presented its pre- and clinical plans for the Multimeric-001 universal flu vaccine to the FDA in a Pre-IND meeting

2007
  • November: Voluntarily terminated first Phase I trial
  • October: Avian flu study in collaboration with Israeli Veterinarian Institute
  • July: Commenced Phase I clinical trial of 1st Generation vaccine
  • June: IPO on the Tel Aviv Stock Exchange, raising about $3m

2006
  • Conducted pre-clinical and toxicology studies
  • Production of 1st Generation vaccine

2005
  • Company operations begin
  • Initial fundraising round completed

2004
  • Initial fundraising round commenced

2003
  • Signed a license agreement with the Weizmann Institute for the in-licensing to BiondVax of the patent relating to the Peptide-based Vaccine for Influenza
  • BiondVax Pharmaceuticals Ltd. established as an Israeli company

1988 - 2002
  • 15 years of R&D led by Prof. Ruth Arnon and her team at the Weizmann Institute of Science
  • Established feasibility of Universal Peptide-based Influenza Vaccine in animals
 

Go Back  Print  Send Page

BiondVax Pharmaceuticals Ltd.
Science Park, 14 Einstein Street

PO Box 4143

Ness Ziona, 74140, Israel

Follow BiondVax on:

              

© BiondVax Pharmaceuticals Ltd, 2007 - 2011 All rights reserved  l   Disclaimer
Email:  info@biondvax.com
Phone:  +972 8 930 2529
Fax:  +972 8 930 2531
Add to Favorites           Make Us Your Home Page           Site Map